Literature DB >> 9815647

O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors.

S Hongeng1, T P Brent, R A Sanford, H Li, L E Kun, R L Heideman.   

Abstract

Chloroethylnitrosoureas (CENUs) are commonly used in the treatment of pediatric and adult central nervous system (CNS) tumors. The antitumor activity of CENUs has been hypothesized to be due to an alkylation occurring at the O6-position of guanine in DNA. The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is responsible for the repair of these potentially cytotoxic lesions and may underlie tumor resistance to CENUs. The current study is the largest report of MGMT levels among newly diagnosed pediatric CNS tumors and the only study that has quantitated MGMT by both biochemical and Western immunoblot assays. Our results show a good correlation between the two methods (r = 0.66). Medulloblastoma/primitive neuroectodermal tumor and ependymoma had the highest level of MGMT, followed by high-grade glioma and low-grade glioma. These data may provide a guide to the use of CENUs in the treatment of pediatric CNS tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815647

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Salvage chemotherapy for metastatic and recurrent ependymoma of childhood.

Authors:  Eric Bouffet; Michael Capra; Ute Bartels
Journal:  Childs Nerv Syst       Date:  2009-04-10       Impact factor: 1.475

2.  Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration.

Authors:  Yohei Shirakami; Max E Gottesman; William S Blaner
Journal:  Carcinogenesis       Date:  2011-11-24       Impact factor: 4.944

3.  Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.

Authors:  Linda R Margraf; Lynn Gargan; Yasmeen Butt; Nirupa Raghunathan; Daniel C Bowers
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

Review 4.  New delivery approaches for pediatric brain tumors.

Authors:  Ian F Pollack; Robert Keating
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

Review 5.  Balancing repair and tolerance of DNA damage caused by alkylating agents.

Authors:  Dragony Fu; Jennifer A Calvo; Leona D Samson
Journal:  Nat Rev Cancer       Date:  2012-01-12       Impact factor: 60.716

6.  Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.

Authors:  Denis Faoro; André O von Bueren; Tarek Shalaby; Davide Sciuscio; Marie-Louise Hürlimann; Lucia Arnold; Nicolas U Gerber; Johannes Haybaeck; Michel Mittelbronn; Stefan Rutkowski; Monika Hegi; Michael A Grotzer
Journal:  J Neurooncol       Date:  2010-09-05       Impact factor: 4.130

7.  Pediatric brain tumors: mutations of two dioxygenases (hABH2 and hABH3) that directly repair alkylation damage.

Authors:  Valentina Cetica; Lorenzo Genitori; Laura Giunti; Massimiliano Sanzo; Gabriella Bernini; Maura Massimino; Iacopo Sardi
Journal:  J Neurooncol       Date:  2009-03-17       Impact factor: 4.130

8.  Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma.

Authors:  Brian R Rood; Huizhen Zhang; Philip H Cogen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

9.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 10.  Childhood ependymoma: a systematic review of treatment options and strategies.

Authors:  Jacques Grill; Chastagner Pascal; Kalifa Chantal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.